Emerging therapies for diabetic macular edema

Stephen G. Schwartz, Harry W. Flynn, Ingrid U. Scott

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are effective in many patients. However, some patients continue to lose vision despite treatment. Emerging therapies may be divided into pharmacologic and surgical interventions. Pharmacologic therapies include locally administered agents, such as corticosteroids and VEGF antagonists, and systemically administered agents, such as ruboxistaurin. No medication is currently approved by the US FDA for the treatment of diabetic macular edema. Surgical approaches include pars plana vitrectomy techniques. As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalExpert Review of Ophthalmology
Issue number2
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Ophthalmology
  • Optometry


Dive into the research topics of 'Emerging therapies for diabetic macular edema'. Together they form a unique fingerprint.

Cite this